Abstract:Abstract The 2019 coronavirus disease (COVID-19) outbreak caused by the SARS-CoV-2 virus is an ongoing global health emergency. However, the virus’ pathogenesis remains unclear, and there is no cure for the disease. We investigated the dynamic changes of blood immune response in patients with COVID-19 at different stages by using 5’ gene expression, T cell receptor (TCR), and B cell receptors (BCR) V(D)J transcriptome analysis at a single-cell resolution. We obtained single-cell mRNA sequencing (scRNA-seq) data of 341,420 peripheral blood mononuclear cells (PBMCs) and 185,430 clonotypic T cells and 28,802 clonotypic B cells from 25 samples of 16 patients with COVID-19 for dynamic studies. In addition, we used three control samples. We found expansion of dendritic cells (DCs), CD14+ monocytes, and megakaryocytes progenitor cells (MP)/platelets and a reduction of naïve CD4+ T lymphocytes in patients with COVID-19, along with a significant decrease of CD8+ T lymphocytes, and natural killer cells (NKs) in patients in critical condition. The type I interferon (IFN-I), mitogen-activated protein kinase (MAPK), and ferroptosis pathways were activated while the disease was active, and recovered gradually after patient conditions improved. Consistent with this finding, the mRNA level of IFN-I signal-induced gene IFI27 was significantly increased in patients with COVID-19 compared with that of the controls in a validation cohort that included 38 patients and 35 controls. The concentration of interferon-α (IFN-α) in the serum of patients with COVID-19 increased significantly compared with that of the controls in an additional cohort of 215 patients with COVID-19 and 106 controls, further suggesting the important role of the IFN-I pathway in the immune response of COVID-19. TCR and BCR sequences analyses indicated that patients with COVID-19 developed specific immune responses against SARS-CoV-2 antigens. Our study reveals a dynamic landscape of human blood immune responses to SARS-CoV-2 infection, providing clues for therapeutic potentials in treating COVID-19.

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity

The type I interferon response in COVID-19: implications for treatment

Viral Invasion and Type I Interferon Response Characterize the Immunophenotypes During COVID-19 Infection

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

Serum Levels of Type I Interferon (IFN-I) is Associated with the Severity of COVID-19.

Blood single cell immune profiling reveals the interferon-MAPK pathway mediated adaptive immune response for COVID-19

Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients

Distinct peripheral inflammatory profiles distinguish COVID-19 from influenza infection, with limited contributions from cytokine storm

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Single-cell landscape of immunological responses in COVID-19 patients

Type I interferon pathway genetic variants in severe COVID-19

Single-cell landscape of immunological responses in patients with COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Dynamic blood single-cell immune responses in patients with COVID-19

Single-cell transcriptome analyses reveal distinct gene expression signatures of severe COVID-19 in the presence of clonal hematopoiesis

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison